Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose study of HP-3060 transdermal therapy in allergic rhinitis
jRCT2080222141Phase 2
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinitis (AR) comparing HP-3060 transdermal with Placebo transdermal (2 arms).
02
Drugs
HP-3060
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on jRCT2080222141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222141.